Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelcitoclax - Ascentage Pharma

Drug Profile

Pelcitoclax - Ascentage Pharma

Alternative Names: APG 1252; APG 1252 12A; Palcitoclax

Latest Information Update: 25 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Class Amines; Aniline compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Phosphonic acids; Piperazines; Piperidines; Pyrroles; Small molecules; Sulfonamides; Sulfones
  • Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Myelofibrosis; Non-Hodgkin's lymphoma; Small cell lung cancer
  • Phase I Neuroendocrine tumours
  • Preclinical Gastric cancer; T-cell lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 23 Oct 2023 Efficacy and adverse events data from a phase Ib trial in Non-small cell lung cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Sep 2022 Pelcitoclax is still in phase I trials for Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion) (NCT04001777)
  • 28 Sep 2022 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (IV) (Ascentage pipeline, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top